过敏史与复发或转移性头颈部鳞状细胞癌患者免疫治疗反应的关系
有过敏史组反应率32.1%(17/52)高于无过敏史组11.1%(4/36),P=0.02;
要点
- 有过敏史组ICI反应率32.1%(17/52)高于无过敏史组11.1%(4/36),P=0.02。
- 有过敏史组中位无进展生存6.0个月 vs 无过敏史组4.2个月(log-rank P=0.04)。
核心结论
- 患者报告的过敏史与复发或转移性头颈部鳞状细胞癌患者的免疫检查点抑制剂反应相关,提示过敏史在评估ICI反应方面可能具有临床实用价值。
主要发现
- 有过敏史组ICI反应率32.1%(17/52)高于无过敏史组11.1%(4/36),P=0.02。
- 有过敏史组中位无进展生存6.0个月 vs 无过敏史组4.2个月(log-rank P=0.04)。
- 有过敏史组中位总生存25.0个月 vs 无过敏史组11.1个月(log-rank P=0.002)。
- 两组在年龄、性别、HPV状态、吸烟状态及T分期和N分期方面相似。
关键数值与推荐
- ICI反应定义为RECIST标准完全缓解或部分缓解。
临床怎么用
- 原文结论指出患者报告的过敏史与ICI反应相关,并强调过敏史在估计ICI反应方面可能具有临床实用价值,未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study examines the association between patient-reported allergy history and immune checkpoint inhibition (ICI) response in patients with recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC). STUDY DESIGN: Retrospective cohort study. SETTING: Academic tertiary care hospital. METHODS: Data were collected from the electronic medical records on baseline age, sex, allergy history, human papillomavirus status, T-stage, N-stage, smoking status, and survival for patients with and without an allergy history. The primary outcome was ICI response defined as complete or partial response by the RECIST criteria. Chi-square and logistic regression analyses were conducted to compare rates and odds of ICI response. Kaplan-Meier analyses were used to compare survival between groups. RESULTS: Our study included 52 patients with an allergy history and 36 patients without an allergy history. The groups were similar in age, sex, HPV status, smoking status, and T- and N-stage. Patients with an allergy history (17/52, 32.1%) had a greater ICI response rate than patients without allergy history (4/36, 11.1%) (P = .02). After adjusting for HPV, patients with allergies had 3.93 (1.19-13.00) times increased odds of ICI response compared to patients without allergies. The median progression-free survival was 6.0 and 4.2 months for patients with and without an allergy history respectively (log-rank, P = .04). The median overall survival was 25.0 and 11.1 months for patients with and without an allergy history respectively (log-rank, P = .002). CONCLUSION: Patient-reported allergy history was associated with ICI response in patients with RMHNSCC, underscoring the potential clinical utility of allergy history in estimating ICI response.
引用
- Alkhatib HH, Maroun CA, Guller M, et al. Allergy History and Immunotherapy Response in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Otolaryngol Head Neck Surg. 2023. PMID: 38123496. doi:10.1002/ohn.582
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。